Vemurafenib may overcome TNF-related apoptosis-inducing ligand (TRAIL) resistance in anaplastic thyroid cancer cells

[1]  P. Wen,et al.  Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Mayerhoefer,et al.  Sustained Response to Vemurafenib in a BRAFV600E-Mutated Anaplastic Thyroid Carcinoma Patient. , 2016, Thyroid : official journal of the American Thyroid Association.

[3]  G. Gunn,et al.  Molecular diagnostics and anaplastic thyroid carcinoma: the time has come to harvest the high hanging fruit , 2016 .

[4]  J. Blay,et al.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.

[5]  S. Mane,et al.  Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. , 2015, Human molecular genetics.

[6]  R. Khosravi‐Far,et al.  Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways , 2014, Cell Death and Disease.

[7]  J. Glaspy,et al.  BRAF V600E inhibition in anaplastic thyroid cancer. , 2013, The New England journal of medicine.

[8]  N. Hay,et al.  Akt-phosphorylated Mitogen-activated Kinase-activating Death Domain Protein (MADD) Inhibits TRAIL-induced Apoptosis by Blocking Fas-associated Death Domain (FADD) Association with Death Receptor 4* , 2010, The Journal of Biological Chemistry.

[9]  Y. Nikiforov,et al.  Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis. , 2009, The Journal of clinical endocrinology and metabolism.

[10]  J. Copland,et al.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. , 2008, Endocrine-related cancer.

[11]  Y. Komada,et al.  Resistance to TRAIL-induced apoptosis caused by constitutional phosphorylation of Akt and PTEN in acute lymphoblastic leukemia cells. , 2008, Experimental hematology.

[12]  P. Hou,et al.  Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. , 2008, The Journal of clinical endocrinology and metabolism.

[13]  N. Mulherkar,et al.  Role of IG20 Splice Variants in TRAIL Resistance , 2008, Clinical Cancer Research.

[14]  A. El‐Naggar,et al.  Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. , 2008, The Journal of clinical endocrinology and metabolism.

[15]  M. Saji,et al.  AKT in thyroid tumorigenesis and progression. , 2007, Endocrinology.

[16]  M. Santoro,et al.  Mutation of the PIK3CA gene in anaplastic thyroid cancer. , 2005, Cancer research.

[17]  N. Mulherkar,et al.  IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC , 2004, Oncogene.

[18]  V. Vasko,et al.  Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer , 2004, Journal of Medical Genetics.

[19]  N. Mitsiades,et al.  Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. , 2002, The American journal of pathology.

[20]  A. Muzikansky,et al.  The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma , 2002, Annals of Surgical Oncology.

[21]  I. Stamenkovic,et al.  Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. , 2000, Cancer research.

[22]  J. Blenis,et al.  FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. , 2000, Immunity.

[23]  D. Lawrence,et al.  Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. , 2000, Immunity.

[24]  V. Dixit,et al.  Apoptosis control by death and decoy receptors. , 1999, Current opinion in cell biology.

[25]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[26]  J. Tschopp,et al.  Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors , 1997, Nature.

[27]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.